<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Orphanet J Rare Dis</journal-id><journal-id journal-id-type="iso-abbrev">Orphanet J Rare Dis</journal-id><journal-title-group><journal-title>Orphanet Journal of Rare Diseases</journal-title></journal-title-group><issn pub-type="epub">1750-1172</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27406229</article-id><article-id pub-id-type="pmc">4941032</article-id><article-id pub-id-type="publisher-id">482</article-id><article-id pub-id-type="doi">10.1186/s13023-016-0482-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10&#x000a0;years&#x02019; treatment</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kampmann</surname><given-names>Christoph</given-names></name><address><email>kampmann@mail.uni-mainz.de</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Perrin</surname><given-names>Amandine</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Beck</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff1"><label/>Section Head for Congenital Heart Defects, Center for Pediatric and Adolescent Medicine, University Medical Center, University of Mainz, Langenbeckstr. 1, Mainz, DE-55101 Germany </aff><aff id="Aff2"><label/>Statistical Programmer, Rare Diseases Business Unit, Global Outcomes Research, Shire, Zug, Switzerland </aff><aff id="Aff3"><label/>Professor Emeritus, Department of Pediatrics, University Medical Center, University of Mainz, Mainz, Germany </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><elocation-id>95</elocation-id><history><date date-type="received"><day>6</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>6</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><related-article related-article-type="corrected-article" id="d30e69" ext-link-type="doi" xlink:href="10.1186/s13023-015-0338-2"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum</title><p>Following the publication of our article &#x0201c;Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10&#x000a0;years&#x02019; treatment&#x0201d; by Kampmann et al. [<xref ref-type="bibr" rid="CR1">1</xref>] we have become aware that the dose of agalsidase alfa was not reported.</p><p>Eligible patients had a Fabry disease diagnosis confirmed by enzyme assay (males) and/or DNA analysis (males and females), were aged &#x02265;14&#x000a0;years at treatment start, and had received agalsidase alfa (Replagal&#x000ae;; Shire, Lexington, Massachusetts, USA) ERT at a dose of 0.2&#x000a0;mg/kg body weight every other week for approximately 10&#x000a0;years.</p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1186/s13023-015-0338-2.</p></fn></fn-group><ref-list id="Bib1"><title>Reference</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kampmann</surname><given-names>C</given-names></name><name><surname>Perrin</surname><given-names>A</given-names></name><name><surname>Beck</surname><given-names>M</given-names></name></person-group><article-title>Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10&#x000a0;years&#x02019; treatment</article-title><source>Orphanet J Rare Dis</source><year>2015</year><volume>10</volume><fpage>125</fpage><pub-id pub-id-type="doi">10.1186/s13023-015-0338-2</pub-id><pub-id pub-id-type="pmid">26416388</pub-id></element-citation></ref></ref-list></back></article>